cis-3,5-dimethyl-1-propylpiperazine | 69837-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: cis-3,5-dimethyl-1-propylpiperazine
• 英文别名: (3R,5S)-3,5-Dimethyl-1-propylpiperazine
• CAS: 69837-33-8
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: DRUWYDLLIVNUSA-DTORHVGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-苯胺基-3-羟基-4-(苯基亚胺)-2-环丁烯-1-酮 、 cis-3,5-dimethyl-1-propylpiperazine 反应 0.17h， 以to give 1-[2-hydroxy-3-(cis-2,6-dimethyl-4-propyl-1-piperazinyl)-4-oxo-2-cyclobuten-1-ylidene]-cis-2,6-dimethyl-4-propylpiperazinium hydroxide inner salt melting at about 218°-227° C的产率得到1-[2-hydroxy-3-(cis-2,6-dimethyl-4-propyl-1-piperazinyl)-4-oxo-2-cyclobuten-1-ylidene]-cis-2,6-dimethyl-4-propylpiperazinium hydroxide
  参考文献：
  名称：

  Piperazinyl cyclobutenones

  摘要：

  本文描述了1-[2-羟基-3-(4-烷基-1-哌嗪基)-4-氧代-2-环丁烯-1-基]-4-烷基哌嗪羟化物内盐及其相关化合物。这些化合物可用作抗病毒剂。它们是由2-苯氨基-3-羟基-4-(苯亚胺基)-2-环丁烯-1-酮和适当的单取代哌嗪制备而成。

  公开号：

  US04138566A1

文献信息

• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Principia Biopharma, Inc.

  公开号：US20160200725A1

  公开（公告）日：2016-07-14

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明公开了一种纤维母细胞生长因子抑制剂（FGFR），因此对于通过抑制FGFR可治疗的疾病具有用处的化合物。同时还公开了包含这种化合物的制药组合物以及制备这种化合物的方法。
• HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：Kurose Noriyuki

  公开号：US20090170832A1

  公开（公告）日：2009-07-02

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted alkyl or the like, one of R 2 and R 4 is a group of formula: —Y—R 5 , wherein Y is —O— or the like, R 5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R 2 and R 4 is hydrogen or optionally substituted alkyl, R 3 is a group of formula: —C(═O)-Z-R 6 , wherein Z is —NR 7 — or —NR 7 —W—, R 6 is optionally substituted cycloalkyl or the like, R 7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is ═N— or the like, with the proviso that compounds wherein R 2 is 2-(morphorino)ethoxy, R 3 is N-(1-adamantyl)carbamoyl and R 1 is benzyl are excluded.
• GAMMA SECRETASE INHIBITORS
  申请人：Wu Wen-Lian

  公开号：US20140018342A1

  公开（公告）日：2014-01-16

  Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
• US4138566A
  申请人：——

  公开号：US4138566A

  公开（公告）日：1979-02-06
• US8324265B2
  申请人：——

  公开号：US8324265B2

  公开（公告）日：2012-12-04